News
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...
The best metric is not weight, but a particularly toxic kind of fat.
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
1d
The Print on MSNMounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trialBoth medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...
As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results